{"nctId":"NCT03127956","briefTitle":"A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","startDateStruct":{"date":"2017-03-21","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":748,"armGroups":[{"label":"Olumacostat Glasaretil Gel, 5.0%","type":"EXPERIMENTAL","interventionNames":["Drug: Olumacostat Glasaretil Gel, 5.0%"]}],"interventions":[{"name":"Olumacostat Glasaretil Gel, 5.0%","otherNames":["DRM01B"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent or assent (for subjects under legal adult age)\n* Completed Week 12 visit of either DRM01B-ACN03 or DRM01B-ACN04 studies.\n* Willing to comply with the protocol. Subjects under legal adult age will be assessed by the investigator as to their ability to comply with the protocol\n* Willing to refrain from using any treatments on the face for acne vulgaris, other than the investigational product, including topical or systemic antibiotics.\n\nExclusion Criteria:\n\n* Abnormal clinically significant findings on physical exam, vital signs or ECG at Week 12 visit of either the DRM01-ACN03 or DMR01-ACN04 studies that would make further treatment with Olumacostat Glasaretil Gel contraindicated, as determined by the Investigator\n* Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions","description":"Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"402","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"518","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"500","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"469","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"485","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"507","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":741},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Application site pruritus","Application site pain","Application site dryness"]}}}